Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/30vKYWg
via IFTTT